Research

Hormonal

Bariatric arterial embolization (BAE) produces modest, transient weight loss (mean 7.0% at 4-5 months, 4.2% at 12 months) in patients with BMI ≥30 who have failed nonoperative management and are ineligible or unwilling to undergo metabolic-bariatric surgery.

If you have obesity (BMI ≥30) and haven't been able to lose weight through diet, exercise, or standard medications, and you are not a candidate for or do not want surgery, BAE might be an option. It involves a minimally invasive procedure to block blood flow to part of the stomach, which reduces hunger hormones. Expect modest weight loss (around 4-7%) over the first year, but it requires ongoing support from a weight management program. It is not a standalone fix and results vary significantly between individuals.

LimitedQualifiesLOW confidence
Patients achieved a mean total body weight loss of 7.0% at 4–5 months’ follow-up and 4.2% at 12 months.
Adham Khalil et al. · Obesity Pillars · 2025

Why this rating

Single-center, retrospective case series with very small sample size (n=5) and no control group.

Source

Establishing a multidisciplinary bariatric arterial embolization program: A two-year clinical experience

Adham Khalil et al. · Obesity Pillars · 2025

DOI 10.1016/j.obpill.2025.100211

case_series · n=31
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →